
|Articles|March 6, 2006
Long-awaited insulin inhaler approved
For diabetic patients reluctant to use insulin for fear of daily injections, their prayers may have been answered. Following years of setbacks and delays, the first new insulin delivery option in more than 80 years, Exubera (insulin human [rDNA origin]) Inhalation Powder from Pfizer Inc., received Food & Drug Administration approval in late January for the treatment of adults with Type 1 and Type 2 diabetes.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Pneumococcal Diseases Require Constant Vaccine Development | NCPA 2025
2
FDA Approves Oral Semaglutide for Risk of MACE for Patients With Diabetes
3
Why Pharmacists Need to Put More Emphasis on Supplement Education | NCPA 2025
4
The Emergence of CGRP-Targeted Therapies is Transforming Migraine Care | NCPA 2025
5